Dossier
major adverse cardiovascular events
Coverage of major adverse cardiovascular events in the Nexus archive.
- Novo Nordisk stock sinks after anti-inflammatory heart drug fails late-stage trial
Novo Nordisk stock declined following the failure of its experimental anti-inflammatory drug ziltivekimab in a late-stage trial. The drug did not reduce major adverse cardiovascular events compared to a placebo in a study involving over 6,300 patients.
- COVID Shots Tied to Lower Risks of Heart Attack, Cardiac Death
Three studies found that COVID-19 vaccines are associated with a lower risk of major adverse cardiovascular events, including heart attack and cardiac death, particularly among older adults. The research involved over 1 million veterans.